NONSMALL CELL LUNG CANCER
Clinical trials for NONSMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new NONSMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for NONSMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Electric field therapy extends life in advanced lung cancer trial
Disease control CompletedThis phase 3 trial tested a portable device that creates electric fields to disrupt cancer cell division in 291 people with stage 4 non-small cell lung cancer that had worsened after initial chemotherapy. Participants wore the device on their chest while continuing standard treat…
Matched conditions: NONSMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: NovoCure GmbH • Aim: Disease control
Last updated Jun 17, 2026 01:45 UTC
-
New antibody combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a new antibody called HMBD-002, given alone or with pembrolizumab, in 48 adults with advanced solid tumors (like lung or breast cancer) that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and s…
Matched conditions: NONSMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Hummingbird Bioscience • Aim: Disease control
Last updated Jun 11, 2026 11:57 UTC
-
Immunotherapy shows promise in advanced lung cancer trial
Disease control CompletedThis study tested a new immunotherapy drug, cemiplimab, against standard chemotherapy for people with advanced non-small cell lung cancer that has a specific marker (PD-L1). The goal was to see if cemiplimab helps patients live longer or keeps their cancer from growing longer tha…
Matched conditions: NONSMALL CELL LUNG CANCER
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jun 10, 2026 13:29 UTC
-
Tailored radiation for lung cancer shows early promise
Knowledge-focused CompletedThis small study tested whether using a patient's tumor genetics to guide radiation dose could work for stage 2-3 non-small cell lung cancer. Only 3 people took part, and the main goal was to see if the approach was safe and feasible. The study is complete, but results are not ye…
Matched conditions: NONSMALL CELL LUNG CANCER
Phase: EARLY_PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Jun 15, 2026 19:03 UTC